Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
Rhea-AI Summary
Latigo Biotherapeutics (Nasdaq: LTGO) priced its upsized initial public offering of 19,200,000 common shares at $18.00 per share, for expected gross proceeds of $345.6 million before fees and expenses. All shares are being sold by Latigo.
Underwriters have a 30-day option to buy up to 2,880,000 additional shares at the public price, less discounts and commissions. Trading on the Nasdaq Global Select Market is expected to begin on August 7, 2026, with closing anticipated on August 10, 2026, subject to customary conditions.
Positive
- IPO gross proceeds expected at $345.6 million before fees
- Upsized IPO with 19.2 million shares at $18.00 per share
- Additional 2.88 million shares available via 30-day underwriter option
- Nasdaq Global Select Market listing expected to begin August 7, 2026
Negative
- None.
News Explained
Latigo has priced an IPO that would add common shares to its total share count if it closes, reducing existing holders’ percentage ownership absent offsetting changes; closing remains expected on
AI-generated analysis. How Rhea-AI works. Not financial advice.
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of
The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol “LTGO.” The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.
Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and has been declared effective by the SEC on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo’s lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain.
Forward-Looking Statements
The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to Latigo’s expected gross proceeds from the initial public offering, the expected date for Latigo common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Latigo’s expectations, beliefs and projections are expressed in good faith and Latigo believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. Latigo undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Company Contacts:
Investors:
Neha Krishnamohan
Latigo Biotherapeutics, Inc.
ir@latigobio.com
Media:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com
